Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Johan Ahlgren"'
Autor:
Heikki Joensuu, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Arja Jukkola, Minna Tanner, Johan Ahlgren, Päivi Auvinen, Outi Lahdenperä, Kenneth Villman, Paul Nyandoto, Greger Nilsson, Paula Poikonen-Saksela, Vesa Kataja, Petri Bono, Jouni Junnila, Henrik Lindman
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(10)
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer. METHODS The Finland Capecitabine Trial (FinXX) is a randomized, open-label, multicenter trial that evaluates i
Autor:
Heikki Joensuu, Vesa Kataja, Minna Tanner, Johan Ahlgren, Pirkko-Liisa Kellokumpu-Lehtinen, Riikka Huovinen, Leena Helle, Henrik Lindman, Päivi Auvinen, M. Leinonen, Greger Nilsson, Kenneth Villman, Arja Jukkola-Vuorinen, R. Kokko, Paul Nyandoto, Outi Saarni, Petri Bono
Publikováno v:
Acta Oncologica (Stockholm, Sweden)
Background. Little information is available about survival outcomes of patients with HER2-positive early breast cancer treated with adjuvant capecitabine-containing chemotherapy with or without trastuzumab. Patients and methods. One thousand and five
Autor:
Petri Bono, Marjo Pajunen, Pirkko-Liisa Kellokumpu-Lehtinen, Raija Asola, Paula Poikonen, R. Kokko, Henrik Lindman, Päivi Auvinen, Vesa Kataja, Riikka Huovinen, Minna Tanner, Arja Jukkola-Vuorinen, Paul Nyandoto, M. Leinonen, Heikki Joensuu, Outi Paija, Kenneth Villman, Leena Helle, Johan Ahlgren, Greger Nilsson
Publikováno v:
Journal of Clinical Oncology. 30:11-18
Purpose Capecitabine is an active agent in the treatment of breast cancer. It is not known whether integration of capecitabine into an adjuvant regimen that contains a taxane, an anthracycline, and cyclophosphamide improves outcome in early breast ca
Autor:
Birgitta Lindh, Jonas Bergh, Hans Nordgren, Elisabet Lidbrink, Lena Malmberg, Carl Blomqvist, John Ohd, Johan Ahlgren, Daniel Bergström, Kenneth Villman
Publikováno v:
European Journal of Cancer. 43:1153-1160
To assess the efficacy and safety of epirubicin, capecitabine and cisplatin (EXC) combination therapy in locally advanced breast cancer (LABC) and investigate the predictive value of selected biomarkers.Newly diagnosed LABC patients received four 3-w
Autor:
Henrik Lindman, Päivi Auvinen, Greger Nilsson, Riikka Huovinen, Minna Tanner, Vesa Kataja, Johan Ahlgren, Sanna Kosonen, Outi Lahdenperä, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Kenneth Villman, Heikki Joensuu, Paula Poikonen-Saksela, R. Kokko, Arja Jukkola-Vuorinen, Paul Nyandoto, Jouni Junnila
Publikováno v:
JAMA Oncology. 3:793
Importance Capecitabine is not considered a standard agent in the adjuvant treatment of early breast cancer. The results of this study suggest that addition of adjuvant capecitabine to a regimen that contains docetaxel, epirubicin, and cyclophosphami
Autor:
Niklas Loman, Henrik Lindman, Oskar T. Johannsson, J. Geisler, Barbro Linderholm, P-O Bendahl, Johan Ahlgren, H Joensuu, Bent Ejlertsen
Publikováno v:
Cancer Research. 76:OT3-02
Background: Adjuvant treatment among the heterogeneous group of triple negative breast cancers (TNBC) is still a challenge. Recently published data indicate that platinum salts may have a role in the treatment of TNBC (v Minckwitz 2014), especially i
Autor:
Arja Jukkola-Vuorinen, Paula Poikonen, Raija Asola, Paul Nyandoto, Lauri Nuortio, Minna Tanner, Kenneth Villman, Marjo Pajunen, Johan Ahlgren, Outi Paija, Pirkko-Liisa Kellokumpu-Lehtinen, Akseli Hemminki, Riikka Huovinen, R. Kokko, Vesa Kataja, Leena Helle, Heikki Joensuu, Petri Bono, Henrik Lindman, Päivi Auvinen, Sirpa-Liisa Lahtela, Greger Nilsson, Kaisa Lehtiö, M. Leinonen
Publikováno v:
The Lancet. Oncology. 10(12)
Standard adjuvant chemotherapy regimens for patients with moderate-to-high-risk early breast cancer typically contain a taxane, an anthracycline, and cyclophosphamide. We aimed to investigate whether integration of capecitabine into such a regimen en
Autor:
Johan Ahlgren, P-L Kellokumpu-Lehtinen, Petri Bono, Minna Tanner, R. Kokko, H Joensuu, Riikka Huovinen, Arja Jukkola-Vuorinen, Henrik Lindman, Päivi Auvinen
Publikováno v:
Cancer Research. 70:PD01-02
Background: Standard adjuvant chemotherapy regimens for patients with moderate-to-high risk early breast cancer typically contain a taxane, an anthracycline and cyclophosphamide. The randomised, phase III FinXX study aimed to investigate whether the
Autor:
T. Jansson, Annika Malmström, Lena Malmberg, C. Ahlin, Johan Ahlgren, Lena M. S. Carlsson, R. Westberg, J. Hansen, J.H. Svensson
Publikováno v:
European Journal of Cancer Supplements. 6:175-176
Autor:
Johan Ahlgren, Minna Tanner, Riikka Huovinen, Heikki Joensuu, R. Kokko, Pirkko-Liisa Kellokumpu-Lehtinen, Petri Bono, Henrik Lindman, Päivi Auvinen, Arja Jukkola-Vuorinen
Publikováno v:
Journal of Clinical Oncology. 28:531-531
531 Background: Interim data from this phase III randomized trial (FinXX) evaluating the integration of capecitabine into anthracycline-/taxane-based adjuvant therapy for early BC were recently published (Lancet Oncol 2009); the present subgroup anal